REG - Physiomics PLC - Result of AGM

PhysiomicsAnnouncement

19/11/2024 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241119:nRSS8525Ma&default-theme=true

RNS Number : 8525M  Physiomics PLC  19 November 2024

19 November 2024

Physiomics plc

("Physiomics" or "the Company")

 

Result of AGM

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce that all resolutions put to
shareholders at the Company's annual general meeting, held earlier today at
the Company's offices in Oxford, were duly passed. Voting was conducted by a
show of hands and inclusive of votes received by the Company by way of proxy.

 

Details of the proxy voting results are shown in the table below.

 

 Ordinary Resolutions                                                Votes For   %       Votes Against  %       Votes Withheld  Votes Total  % of ISC Voted
 1. Approval of the accounts                                         13,702,827  98.48%  210,852        1.52%   5,844           13,919,523   6.8%
 2. Re-appointment of Dr Peter Sargent as a Director of the Company  12,408,973  97.73%  287,661        2.27%   1,222,889       13,919,523   6.8%
 3. Re-election of Dr Shalabh Kumar as a Director of the Company     12,408,973  97.73%  287,661        2.27%   1,222,889       13,919,523   6.8%
 4. Appointment and renumeration of auditor                          13,697,496  98.45%  216,183        1.55%   5,844           13,919,523   6.8%
 5. Authority to allot shares                                        13,328,063  95.79%  585,616        4.21%   5,844           13,919,523   6.8%
 Special Resolution
 6. Disapplication of shareholders' statutory pre-emption rights     12,108,403  87.03%  1,805,276      12.97%  5,844           13,919,523   6.8%

ISC - Issued Share Capital

 

 

Enquiries:

 

Physiomics
plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGPGBCGUPCGQB